Melphalan for Acute Myeloid Leukemia

"Pembrolizumab is the most commonly prescribed treatment for unresectable melanoma and can also be beneficial in managing microsatellite instability high, reducing recurrence risk, or controlling disease progression."

"This clinical study has ended its recruitment phase, with the primary posting on September 28th 2016 and last edit being made on September 7th 2022. However, for those interested in other trials related to leukemia, myelocytic or acute diseases there are 507 studies currently running while 1393 participants can join Pembrolizumab's trial."

"Currently, 1393 trials involving Pembrolizumab are running. Of those experiments, 159 have reached the third stage of testing. Although Scottsdale, Arizona is home to most clinical trials for this medication, there are an additional 41020 sites also hosting research studies."

"Our research team at Power has assigned a score of 2 to Pembrolizumab's safety, as this is still in the Phase 2 trial stage and there are data points suggesting its security but not yet indicating efficacy."

"The qualifications for this trial state that the minimum age to enroll is 18, while the maximum age permitted is 78."

"This clinical trial is in search of 20 participants between 18 and 78 years old dealing with the diagnosis of non-favorable risk acute myelocytic leukemia. Additionally, applicants must be in remission or have achieved a prior complete response (CR) to qualify for enrollment."

"This trial is no longer acceptiong patients. It was first announced on September 28th, 2016 and its last update was on Septmeber 7th, 2022. If you are searching for other trials in the same area of research, 507 studies with acute myelocytic leukemia as an indication are open to participation and 1393 studies that utilize Pembrolizumab have available vacancies."